Actively Recruiting
The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial
Led by Zhongnan Hospital · Updated on 2025-12-26
196
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of artificial intelligence (AI) technology to improve health education among patients with haematological cancers such as leukaemia, lymphoma, multiple myeloma, and related disorders. The study aims to assess how AI-assisted education affects patients' understanding of clinical trials and their intention to participate in them. This research seeks to explore the benefits of AI-powered chatbots in delivering personalized health information and supporting patient decision-making for clinical trial participation. Participants are divided into two groups. One group receives standard health education plus clinical trial-specific education delivered through an AI robot featuring voice interaction and multimedia displays to enhance understanding. The other group receives only routine health education from healthcare staff covering disease knowledge and treatment but without dedicated clinical trial information. This is a randomized controlled trial designed to compare these two approaches. During the study, participants will be assessed on their intention to participate in clinical trials at the start of enrollment and one week after completing the intervention. Researchers will also evaluate user experience seven days post-intervention. The study involves collecting data on patients' cognitive levels, attitudes, and participation intentions to understand the impact of AI-assisted education. The total participation period includes a one-week intervention and post-intervention assessments.
CONDITIONS
Brief Title
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older with clear consciousness
- Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria)
- Able to understand health education content and possess basic communication skills
- Willing to participate in the study and sign an informed consent form
You will not qualify if you...
- Patients with cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension
- Anticipated hospital stay shorter than 3 days, making intervention completion unfeasible
- Receiving end-of-life palliative care
- Previous participation in other clinical trial education programmes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) to determine eligibility and obtain informed consent
Duration - 1 week
Participants receive health education; either standard routine education delivered by healthcare staff or enhanced clinical trial-specific education delivered via an AI robot to improve understanding and intention to participate in clinical trials.
1 baseline visit and 1 follow-up visit within 7 days after intervention completion
Trial Site Locations
Total: 1 location
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071
Actively Recruiting
Research Team
F
Fuling Zhou
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here